GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it…
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12,…
Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech…
Full-Year Revenues of $25.4 million and Net Income of $3.5 millionMISSISSAUGA, Canada, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems…
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies…
KdT has formed a new company to develop NGM313 in a rare disease indicationNGM Bio will receive up to $608…
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2…
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept…
Aarhus, Denmark, 19 December 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments…
Fast track designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenstrom’s MacroglobulinemiaSAN FRANCISCO, Dec. 19,…